Get started
Author

Robbe Saesen

Observed names: R Saesen, R. Saesen, Saesen, Robbe, Saesen, robbe
Institution: Sciensano (Belgium)
ORCID: 0000-0003-4460-0860
Observed ORCID: 0000-0003-4460-0860
OpenAlex ID: A5040901080
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer
2023 · Robbe Saesen, Mieke Van Hemelrijck, et al. · European Journal of Cancer · 104
PDF
Creasensor: SIMPLE technology for creatinine detection in plasma
2017 · Francesco Dal Dosso, Deborah Decrop, et al. · Analytica Chimica Acta · 52
PDF
Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making
2020 · Robbe Saesen, Stéphane Lejeune, et al. · Frontiers in Pharmacology · 30
PDF
How to balance valuable innovation with affordable access to medicines in Belgium?
2022 · Steven Simoens, Khadidja Abdallah, et al. · Frontiers in Pharmacology · 22
PDF
Patients’ knowledge, preferences, and perspectives about data protection and data control: an exploratory survey
2024 · Teodora Lalova-Spinks, Robbe Saesen, et al. · Frontiers in Pharmacology · 16
Real-world data in oncology: a questionnaire-based analysis of the academic research landscape examining the policies and experiences of the cancer cooperative groups
2023 · R. Saesen, D. Lacombe, et al. · ESMO Open · 15
PDF
Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer
2021 · Robbe Saesen, Denis Lacombe, et al. · European Journal of Cancer · 15
PDF
Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer
2025 · Fábio Cardoso Borges, Winette T A van der Graaf, et al. · The Lancet Oncology · 14
Establishing treatment optimisation as part of personalised medicine development
2019 · Denis Lacombe, Gianluca Quaglio, et al. · European Journal of Cancer · 14
Advancing academia-driven treatment optimisation in oncology: Launch of the EMA Cancer Medicines Forum
2022 · Robbe Saesen, Claire Espinasse, et al. · European Journal of Cancer · 13
PDF
How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer
2022 · Robbe Saesen, Georgios Kantidakis, et al. · Frontiers in Pharmacology · 12
PDF
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
2020 · Stefanie Broes, Robbe Saesen, et al. · Clinical and Translational Science · 12
PDF
Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments
2023 · Robbe Saesen, Kevin Depreytere, et al. · BMC Medical Research Methodology · 10
PDF
How to scale up telemedicine for cancer prevention and care? Recommendations for sustainably implementing telemedicine services within EU health systems
2025 · Victoria Leclercq, Robbe Saesen, et al. · Journal of Cancer Policy · 7
Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders
2022 · M Dooms, R Saesen, et al. · Frontiers in Pharmacology · 7
Involvement of the European Medicines Agency in multi-stakeholder regulatory science research projects: experiences of staff members and project coordinators
2023 · Robbe Saesen, Matilde Machado, et al. · Frontiers in Medicine · 3
COVID-19 clinical trials: see it big and keep it simple
2020 · Robbe Saesen, Isabelle Huys · BMJ Evidence-Based Medicine · 2
PDF
HIV-positive men as a key population for fighting HIVDR in Africa
2018 · Jennifer Herrmann, Jenny Lushaba, et al. · Transdisciplinary Insights · 2
PDF
The Belgian Cancer Inventory: Co-creating a framework for monitoring the implementation of cancer policies and associated inequalities
2024 · Robbe Saesen, Gabrielle Schittecatte, et al. · Journal of Cancer Policy · 1
Accelerating regulatory approval of anticancer therapies: Benefits, drawbacks and recommendations for a more sustainable approach
2021 · Robbe Saesen, Denis Lacombe, et al. · Journal of Cancer Policy · 1
The Future of Cancer Knowledge Management in Europe: A Participatory Foresight Study
2026 · L Abboud, R Saesen, et al. · European Journal of Public Health
PDF
Leveraging artificial intelligence to strengthen cancer care in Belgium: a policy brief from the Belgian Europe’s Beating Cancer Plan Mirror Group
2026 · E. Cauët, R. Saesen, et al. · ESMO Real World Data and Digital Oncology
PDF
Deploying Telemonitoring Ecosystems for Cancer Care Across Europe: The eCAN and eCAN Plus Joint Action Project Experience
2026 · Michalis Gemenaris, Stelios Mappouras, et al. · Proceedings - IEEE Symposium on Computer-Based Medical Systems
Advancing TELEMEDICINE adoption into European cancer care through the Joint Actions eCAN and eCAN+
2025 · Chloë Mbarushimana, Robbe Saesen, et al. · Journal of Cancer Policy
Boosting telemedicine use in cancer care: passing the baton between the Joint Actions eCAN and eCAN+
2025 · R Saesen, V Leclercq, et al. · European Journal of Public Health
Works count: 36
Citation count: 352
H-index: 12
I10-index: 13
Year
Topic
Type